FDA approval of Biogen Idec drug Tysabri brings cheer to Hillerød  

The FDA has approved Biogen Idec's drug for the treatment of MS in just 6 months, which bodes well for the company's factory currently under construction in Hillerød, Denmark

The FDA has approved Biogen Idec's promising drug Tysabri for the treatment of multiple sclerosis (MS) in just 6 months. According to regional newspaper Frederiksborg Amts Avis the approval bodes well for Biogen Idec's production plant currently under construction in Hillerød, north of Copenhagen, which will be producing the drug from 2008.


The production factory in Hillerød will mainly produce Tysabri for the European market. Birgitte Thygesen, information manager of Biogen Idec says that the company is waiting for approval from the European Health Authorities, which have accepted an application based on one year's test results.


Tysabri [pronounced Tie-SAB-ree – Ed.] is a recombinant humanized monoclonal antibody produced in murine (i.e. mouse) myeloma cells. The new drug could be an important breakthrough for more than one million patients worldwide who suffer from MS. The preliminary test results show that patients using Tysabri experience a reduction in attacks of dizziness, numbness, paralysis and disturbances of vision. The news is reported by national daily newspaper Berlingske Tidende.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×